PDS Biotechnology Targets H2 2026 Phase 2 Trial Starts, Extends Cash Runway
PDS Biotechnology’s Q1 2026 earnings call focused on strategic pipeline advancements and confirmed a cash runway through 2027. Management outlined plans to file INDs for its lead OncoPhage candidates by midyear and to commence Phase 2 trials in H2 2026.
1. Pipeline Advancements
Management detailed progress toward IND filings for its lead OncoPhage immunotherapy candidates and laid out plans to commence Phase 2 clinical trials in the second half of 2026.
2. Financial Outlook
Executives confirmed a cash runway extending through 2027 to support ongoing clinical development and manufacturing scale-up, without disclosing specific Q1 revenue or EPS figures.
Related News
AVGO
Nvidia Predicts $91B Q3 Sales, Boosts Dividend and $80B Buyback; Broadcom Poised for AI Inference Growth
AVGO•
NVDA
Nvidia’s AI Chip Revenue Forecast Beats Estimates but Shares Drop 1.3%
NVDA•
URBN
Urban Outfitters Q1 Sales Soar 11% to $1.5B, EPS Up 12%
URBN•
VBCG
Vanguard’s BondBuilder ETFs Gather $242M in Two Months with 0.08% Fees
VBCG•
TOL
Toll Brothers Beats Q2 Revenue Guidance by $110M, Raises Delivery and Buyback Plans
TOL•
Sources
F